AlenCiken

final study suports + 55$m financing secured

NASDAQ:PTGX   Protagonist Therapeutics, Inc

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.